News
$Immix Biopharma(IMMX.US$ Immix Biopharma Presents NXC-201 Data At 65th American Society Of Hematology Annual Meeting In 9 Relapsed/Refractory AL Amyloidosis Patients
Benzinga· 4 mins ago
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy
Updated results will be communicated at the presentation time December 10, 2023![]()
Benzinga· 4 mins ago
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy
Updated results will be communicated at the presentation time December 10, 2023
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
